In a lipopolysaccharide (LPS)-induced mouse model, GLP-1 expression was reduced in peripheral blood and increased in alveolar lavage fluid and lung tissues, which was inhibited by liraglutide, a GLP-1RA, and was able to suppress LPS-induced lung injury in mice, inhibit polymorphonuclear neutrophil (PMN) extravasation, reduce the number of apoptotic cells in the lung, inhibit macrophage accumulation 48 and Liraglutide also has anti-inflammatory and airway-protective effects by modulating the PKA/NF-B signaling pathway to improve histopathological changes and airway inflammation in mice, inhibiting E-selectin overexpression and reducing mucus secretion and cupped cell proliferation
HIMSs compounding pharmacy apparently cracked the same problem using an undisclosed specialized formulation that has never been tested in any clinical trial, never been reviewed by the FDA, and has zero pharmacokinetic data demonstrating actual bioavailability
Eli Lilly took a similar actionin August
EBioMedicine 70 , 103536 (2021)
Kostev K, Rex J, Rockel T, Heilmaier C
Risk Factors for Liver Damage Several factors can increase the risk of liver damage with semaglutide: Pre-existing Liver Conditions: Patients with liver diseases like hepatitis or cirrhosis may be at higher risk and should be closely monitored
